Protein Methylation in Diabetic Kidney Disease

Area of Science:

• Nephrology
• Molecular Biology
• Epigenetics

Background:

• Chronic kidney disease (CKD) is characterized by persistent renal dysfunction, with diabetes being the primary cause, leading to diabetic kidney disease (DKD).
• Renal fibrosis is a common pathological outcome in DKD, yet its underlying mechanisms, particularly post-transcriptional and epigenetic regulations, remain incompletely understood.
• There is a significant unmet need for innovative therapeutic strategies to prevent, halt, treat, and reverse DKD.

Purpose of the Study:

• To explore the role of protein methylation, a critical post-translational modification, in the context of diabetic kidney disease.
• To review the current clinical research status and future prospects of protein methyltransferase (PMT) inhibitors for DKD treatment.
• To deepen the understanding of DKD's molecular mechanisms by focusing on protein methylation.

Main Methods:

• Literature review focusing on protein methylation (histone and non-histone) and its connection to DKD.
• Analysis of current clinical research on PMT inhibitors.
• Emphasis on post-transcriptional and epigenetic regulatory aspects of renal fibrosis in DKD.

Main Results:

• Protein methylation is identified as an essential post-translational modification implicated in DKD pathogenesis.
• Existing reviews predominantly focus on DNA methylation, highlighting a gap in understanding protein methylation's role.
• Protein methyltransferase inhibitors show potential as a therapeutic avenue for DKD.

Conclusions:

• Protein methylation plays a significant role in the molecular mechanisms of diabetic kidney disease.
• Targeting protein methylation via PMT inhibitors presents a promising strategy for novel DKD treatments.
• Further research into protein methylation is essential for advancing DKD therapeutic development.